Lebrest

Indonesia • Ferron Par Pharmaceuticals

Indication

Adjuvant treatment
Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. Extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.

Treatment in postmenopausal women with hormone-dependent advanced breast cancer
Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antiestrogens. Preoperative therapy in postmenopausal women with localized hormone receptor positive breast cancer, to allow subsequent breast-conserving surgery in women not originally considered candidates for this type of surgery. Subsequent treatment after surgery should be in accordance with standard of care.

Composition

Letrozole 2.5 mg

Package

3 blisters of 10 tablets

Dosage Forms

Tablet

ATC Classification

L02B

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Not Recommended
This item should not be used while operating heavy machinery.
Pregnancy
Not Recommended
This item is not safe for use during pregnancy.
Lactation
Not Recommended
This item is not safe for use during lactation.

Dosage

18 Years Old and Above

The recommended dose of letrozole is 2.5 mg once daily.

In the adjuvant and extended adjuvant setting, treatment with letrozole should continue for 3 years or until tumor relapse occurs, whichever comes first.

In patients with metastatic disease, treatment with letrozole should continue until tumor progression is evident.

Food does not affect the absorption of letrozole and the drug may be administered without regard to meals.

Elderly Patients

No dose adjustment is required for elderly patients.

Patients with Hepatic Impairment

No dosage adjustment is required for patients with mild to moderate hepatic impairment.

Patients with Renal Impairment

No dosage adjustment is required for patients with mild to moderate renal impairment (creatinine clearance ≥10 ml/minute).